PeerView Oncology

 

PeerView Oncology
Avatar

2020 Update on CDK4/6 Inhibitors in BC: FDA-Approved Practice Changing Palbociclib, Ribociclib & Abemaciclib - What Are the Differences in Dosing, ORR & AE?

By PeerView Oncology FEATURING Joyce O'Shaughnessy, Sara Tolaney
By PeerView Oncology FEATURING Joyce O'Shaughnessy, Sara Tolaney
0 views
October 29, 2020
In this activity, breast cancer experts Joyce O’Shaughnessy, MD, and Sara M. Tolaney, MD, MPH, ...
read more ↘
Comments 2
Login to view comments. Click here to Login

Featured Video

06:14
Lilly Medical Affairs

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Feat. J. O’Shaughnessy

Featured Video

05:59
Lilly Medical Affairs

Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and …

Feat. J. O’Shaughnessy
Breast
11:49
PeerView Oncology

2020 Update on CDK4/6 Inhibitors in BC: FDA-Approved Practice Changi…

Feat. J. O'Shaughnessy, S. Tolaney